Monday, June 30, 2014

Sarilumab at the EULAR 2014 Meeting in Paris


I hadn’t heard much in a while about sarilumab, fully human monoclonal antibody (MAB) against IL-6R alpha. So I have been very interested in presentations at the EULAR 2014 Meeting in Paris.

[OP0028]
M. Genovese and colleagues presented: “EFFECTS OF SARILUMAB PLUS MTX ON CLINICAL, RADIOGRAPHIC, AND FUNCTIONAL ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY”. N=1197!!! Conclusions: “In this phase 3 study, both sarilumab doses (150 mg and 200 mg q2w), in combination with MTX, demonstrated efficacy in pts with active RA who had inadequate response to MTX. Both sarilumab doses met clinical, radiographic, and functional endpoints. Clinical response was maintained throughout the 52-wk study period. Infection SAEs and laboratory abnormalities with sarilumab are consistent with IL-6 signaling blockade.” This looks much better than the studies presented a year ago.

[THU0275]
S. Fiore and collegaegues looled at: “IL-6 RECEPTOR (IL-6R) BLOCKADE WITH SARILUMAB REDUCED CIRCULATING MARKERS RELATED TO
SYNOVIAL INFLAMMATION AND STRUCTURAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN A PHASE 2 “.STUDY” Conclusions: “Sarilumab treatment in patients with RA resulted in significant dose-dependent reduction in MMP-generated neo-epitope biomarkers related to joint and tissue turnover.”

I’m a bit more confident in the future of sarilumab. At least it looks much better than a year ago. This year I’d like to say: sarilumab get to the market! Hope it won’t take too long.

Links:

No comments:

Post a Comment